Foundation Medicine, ARIAD announce collaboration to study AP26113 Foundation Medicine and ARIAD announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.
ARIAD announces CHMP adopts final opinion on Iclusig ARIAD Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events. The company said, "We are now well positioned to complete pricing and reimbursement negotiations in Europe and to ensure that Iclusig is available to appropriate Philadelphia-chromosome positive leukaemia patients."